Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

被引：0

作者：

Sayegh, N. ^{[1
]}

Jo, Y. Jung ^{[1
]}

Gebrael, G. ^{[1
]}

Tripathi, N. ^{[1
]}

Chigarira, B. ^{[1
]}

Srivastava, A. ^{[1
]}

Nordblad, B. ^{[1
]}

Dal, E. ^{[1
]}

Chehade, C. Hage ^{[1
]}

Maughan, B. L. ^{[1
]}

Gupta, S. ^{[1
]}

Agarwal, N. ^{[1
]}

Swami, U. ^{[1
]}

机构：

[1] Univ Utah Hlth, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2380P

引用

页码：S1212 / S1212

页数：1

共 50 条

[41] Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
Zhao, Yanan
Wu, Di
Yao, Quanjun
Yuan, Hang
Hu, Hongtao
Li, Hailiang
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 49 (02) : 147 - 154
[42] Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer
Zhou, Zi-Chao
Chen, Kai-Yan
Li, Na
Xie, Ming-Ying
Sheng, Jia-Min
Fan, Yun
Huang, Zhi-Yu
THORACIC CANCER, 2022, 13 (16) : 2291 - 2300
[43] Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
Sabate Gallego, Monica
Perez Esquirol, Eulalia
Garcia Dolade, Nuria
Vidal Guitart, Xavier
Carreras Soler, Maria-Josep
Farriols Danes, Anna
Felip, Enriqueta
Brana, Irene
Carles Galceran, Joan
Morales Barrera, Rafael
Munoz-Couselo, Eva
Escasany, Antonia Agusti
FRONTIERS IN MEDICINE, 2022, 9
[44] From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma
Hussain, Syed A.
Birtle, Alison
Crabb, Simon
Huddart, Robert
Small, Diane
Summerhayes, Maxwell
Jones, Robert
Protheroe, Andrew
EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (06): : 486 - 500
[45] Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis
Nishijima, Tomohiro F.
Shachar, Shlomit S.
Nyrop, Kirsten A.
Muss, Hyman B.
ONCOLOGIST, 2017, 22 (04): : 470 - 479
[46] Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI).
Shah, Manasee
Devine, Jacob
Wang, Sam
Hepp, Zsolt
Shah, Sonali
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[47] TP53 DISRUPTIVE MUTATION PREDICTS PLATINUM-BASED CHEMOTHERAPY AND PD-1/PD-L1 BLOCKADE RESPONSE IN UROTHELIAL CARCINOMA
Jin, Kaifeng
Liu, Zhaopei
Wang, Zewei
JOURNAL OF UROLOGY, 2024, 211 (05): : E869 - E870
[48] TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma
Jin, Kaifeng
Xu, Jingtong
Su, Xiaohe
Xu, Ziyue
Li, Bingyu
Liu, Ge
Liu, Hailong
Wang, Yiwei
Zhu, Yu
Xu, Le
Zhang, Weijuan
Liu, Zhaopei
Wang, Zewei
Chang, Yuan
Xu, Jiejie
JOURNAL OF PATHOLOGY, 2024, 263 (02): : 139 - 149
[49] Examination of PD-1/PD-L1 inhibitor use and adverse events in a real-world setting.
Irwin, Debra E.
Brady, Brenna L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
Wei, Xiao X.
Werner, Lillian
Teo, Min Y.
Rosenberg, Jonathan E.
Koshkin, Vadim S.
Grivas, Petros
Szabados, Bernadett
Morrison, Laura
Powles, Thomas
Carril-Ajuria, Lucia
Castellano, Daniel
Velho, Pedro Isaacsson
Hahn, Noah M.
McKay, Rana R.
Raggi, Daniele
Necchi, Andrea
Kanesvaran, Ravindran
Alerasool, Parissa
Gaines, Jacob
Galsky, Matthew
Bellmunt, Joaquim
Sonpavde, Guru
JOURNAL OF UROLOGY, 2021, 205 (02): : 414 - 419

← 1 2 3 4 5 →